Prospective evalution of pregnant women with suspected acute toxoplasmosis treated in a reference prenatal care clinic at a university teaching hospital in Southern Brazil

Evangelista, Fernanda Ferreira; Mantelo, Francini Martini; Lima, Keller Karla de; Marchioro, Ariella Andrade; Beletini, Lucimara Fátima; Souza, Aloísio Henrique Pereira de; Santana, Priscila Laet; Riedo, Cristiane de Oliveira; Higa, Lourenço Tsunetomi; Falavigna-Guilherme, Ana Lúcia

doi:10.1590/s1678-9946202062046

Cited by 3 publications

(1 citation statement)

References 37 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary eye complications are uncovered in 50% of patients, with cataracts, microphthalmia and strabismus being the most prevalent [ 39 ]. In a recent study from Brazil, a prevalence of CT of 1.2 cases/1000 live births were reported [ 98 ]. In another Brazilian cohort, retinochoroiditis was reported in 71.4% of patients.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes in Children with Congenital Toxoplasmosis—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Even in the absence of manifestations at birth, children with congenital toxoplasmosis (CT) may develop serious long-term sequelae later in life. This systematic review aims to present the current state of knowledge to base an informed decision on how to optimally manage these pregnancies and children. For this, a systematic literature search was performed on 28th July 2022 in PubMed, CENTRAL, ClinicalTrials.gov, Google Scholar and Scopus to identify all prospective and retrospective studies on congenital toxoplasmosis and its long-term outcomes that were evaluated by the authors. We included 31 research papers from several countries. Virulent parasite strains, low socioeconomic status and any delay of treatment seem to contribute to a worse outcome, whereas an early diagnosis of CT as a consequence of prenatal screening may be beneficial. The rate of ocular lesions in treated children increases over time to 30% in European and over 70% in South American children and can be considerably reduced by early treatment in the first year of life. After treatment, new neurological manifestations are not reported, while ocular recurrences are observed in more than 50% of patients, with a mild to moderate impact on quality of life in European cohorts when compared to a significantly reduced quality of life in the more severely affected South American children. Though CT is rare and less severe in Europe when compared with South America, antenatal screening is the only effective way to diagnose and treat affected individuals at the earliest possible time in order to reduce the burden of disease and achieve satisfying outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes in Children with Congenital Toxoplasmosis—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

Gestational toxoplasmosis treatment changes the child’s prognosis: A cohort study in southern Brazil

Gomes Ferrari Strang,

Ferrar,

Falavigna-Guilherme

2023

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Background We evaluate the drug treatment for pregnant women with acute toxoplasmosis to reduce the risk of congenital infection, side effects (prenatal and postnatal treatment in children) and the hazard of discontinuing the infant’s medication. Methods We conducted a prospective cohort study to assess the risks of congenital toxoplasmosis among children born to acutely infected women with and without treatment. We examined the relationship between "exposed" and "infected children", "number of infant neutrophils", "prenatal" and "postnatal treatment". Factor analysis of mixed data (FAMD) was used to analyze the data. All children started treatment at the hospital. Findings Between 2017 and 2021, 233 pregnant women were evaluated at the University Hospital of Maringá; ninety-four met criteria for acute gestational toxoplasmosis. We followed up 61 children; eleven (18%) had the infection confirmed and 50 (82%) were free of toxoplasmosis (exposed). Children born to untreated mothers have 6.5-times higher risk of being infected; the transmission rate among untreated mothers was 50% versus 8.3% among treated ones. Three decreasing values of immunoglobulin G were a security parameter for stopping the child’s medication in the exposed group (50/61). Neutropenia was the leading side effect among children and the infected had a 2.7 times higher risk. There was no correlation between maternal use of pyrimethamine and children’s neutropenia. Interpretation The follow-up of women with acute T. gondii infection and their children, through a multidisciplinary team, availability of anti-T. gondii serology and pre- and post-natal treatments reduced the risk of toxoplasmosis transmission.

show abstract

Medicines for Malaria Venture Pandemic Box In Vitro Screening Identifies Compounds Highly Active against the Tachyzoite Stage of Toxoplasma gondii

dos Santos,

Oliveira Costa,

Vaz

et al. 2023

TropicalMed

View full text Add to dashboard Cite

Toxoplasmosis is a disease that causes high mortality in immunocompromised individuals, such as AIDS patients, and sequelae in congenitally infected newborns. Despite its great medical importance, there are few treatments available and these are associated with adverse events and resistance. In this work, after screening the drugs present in the Medicines for Malaria Venture Pandemic Box, we found new hits with anti-Toxoplasma gondii activity. Through our analysis, we selected twenty-three drugs or drug-like compounds that inhibited the proliferation of T. gondii tachyzoites in vitro by more than 50% at a concentration of 1 µM after seven days of treatment. Nineteen of these compounds have never been reported active before against T. gondii. Inhibitory curves showed that most of these drugs were able to inhibit parasite replication with IC50 values on the nanomolar scale. To better understand the unprecedented effect of seven compounds against T. gondii tachyzoites, an ultrastructural analysis was carried out using transmission electron microscopy. Treatment with 0.25 µM verdinexor, 3 nM MMV1580844, and 0.25 µM MMV019724 induced extensive vacuolization, complete ultrastructural disorganization, and lytic effects in the parasite, respectively, and all of them showed alterations in the division process. Treatment with 1 µM Eberconazole, 0.5 µM MMV1593541, 1 µM MMV642550, 1 µM RWJ-67657, and 1 µM URMC-099-C also caused extensive vacuolization in the parasite. The activity of these drugs against intracellular tachyzoites supports the idea that the drugs selected in the Pandemic Box could be potential future drugs for the treatment of acute toxoplasmosis.

show abstract

Prospective evalution of pregnant women with suspected acute toxoplasmosis treated in a reference prenatal care clinic at a university teaching hospital in Southern Brazil

Abstract: This is an open-access article distributed under the terms of the Creative Commons Attribution License.

Cited by 3 publications

References 37 publications

Long-Term Outcomes in Children with Congenital Toxoplasmosis—A Systematic Review

Long-Term Outcomes in Children with Congenital Toxoplasmosis—A Systematic Review

Gestational toxoplasmosis treatment changes the child’s prognosis: A cohort study in southern Brazil

Medicines for Malaria Venture Pandemic Box In Vitro Screening Identifies Compounds Highly Active against the Tachyzoite Stage of Toxoplasma gondii

Contact Info

Product

Resources

About